Financings Of The Fortnight Looks For A Strong IPO Year To Pick Up Further In Second Half
This article was originally published in The Pink Sheet Daily
Looking ahead to Start-Up’s third annual life science venture survey, optimism seems on the upswing and FOTF looks for an even stronger pace of IPOs in the second half of 2013. Plus news on financings by Agios, Merrimack, OncoMed and Alcresta.
You may also be interested in...
After a slow August and early September, Wall Street is preparing for four biotech IPOs. Biotech IPOs have been on fire, outperforming even the vigorous biotech indices. But the question remains – can public investors get too much of a good thing?
The Massachusetts nutritionals company has guaranteed it can transition from a development company to a commercial company without the help of a partner due to a recent infusion of cash but hopes to strike partnerships for certain indications and regions once the product gets to market.
Former Alnara founders Alexey Margolin and Robert Gallotto have begun a new venture that includes Alnara’s previous investors.